We conducted a study that included systematic summaries (SR) and comparative tests (RCTs) to analyze the efficacy and safety of cannabis-based drugs in patients with mental disorders.
Five different data sources were systematically searched (from 2016 to August 2018) and included 4 SRs and 14 MDGs (with a total of 1629 participants).
Diagnosis found included: dementia, cannabis and opioid dependence, psychoses / schizophrenia, anxiety disorders, post-traumatic stress disorder, anorexia nervosa, ADHD and Tourette's syndrome. The varying results were too varied to allow meta-analysis. Therefore, the method used was narrative analysis.
THC and CBD-based drugs, administered as a supplement to psychotherapy and pharmacotherapy, have been associated with the improvement of the symptoms of psychiatric disorders, but not with their resolution. Side effects still occurred, but serious side effects were reported only in very few cases.
In order to offer reliable recommendations, more RCTs, consistent measures and benchmarking are needed.
Key words: mental disorders, cannabis, cannabinoids, THC, CBD, therapeutic cannabis, treatment
Authors: Eva Hoch, Dominik Neimann, Rupert von Keller, Miriam Schneider, Chris M. Friemel, Ulrich W Preuss, Alkomiet Hasan, Oliver Pogarell.
You can read more of this study at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595000/. The whole study is in English.
Photo source: pixabay.com (by John Hain)